Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yael Rachamin, Christoph Jakob Ackermann, Oliver Senn, Thomas Grischott
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7cceb14eaa2541c6b333e1e614f3fbb9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7cceb14eaa2541c6b333e1e614f3fbb9
record_format	dspace
spelling	oai:doaj.org-article:7cceb14eaa2541c6b333e1e614f3fbb92021-12-02T20:13:04ZPrice trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.1932-620310.1371/journal.pone.0259936https://doaj.org/article/7cceb14eaa2541c6b333e1e614f3fbb92021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0259936https://doaj.org/toc/1932-6203Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly prices of oncological drugs introduced over the last 15 years in Switzerland. We identified all oncological drugs newly reimbursed by mandatory health insurance in 2005-2019, and searched public repositories for their package prices, indications with approval dates, and treatment regimens for the calculation of (indication-specific) monthly prices. We found 81 products covering 77 different substances (39.5% protein kinase inhibitors, 21.0% monoclonal antibodies). Most indications related to the topography "blood", followed by "lung and thorax" and "digestive tract". From 2005-2009 to 2015-2019, the median monthly product price over all distinct indications of all products decreased by 7.56% (CHF 5,699 [interquartile range 4,483-7,321] to CHF 5,268 [4,19-6,967]), whereas it increased by 73.7% for monoclonal antibodies. In December 2019, six products had monthly prices over CHF 10,000, all approved for hematological or dermatological cancers. Our analysis suggests that individual price developments of oncological drugs are presently not the major driver of rising cancer treatment costs. However, rising launch prices of some new, mostly hematological drugs are of concern and require continued monitoring.Yael RachaminChristoph Jakob AckermannOliver SennThomas GrischottPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11, p e0259936 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yael Rachamin Christoph Jakob Ackermann Oliver Senn Thomas Grischott Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
description	Increasing oncological treatment costs are a major global concern with the risk of entailing two-tiered health care. Among cost determining factors is the price of individual drugs. In recognition of the central role of this factor, we present a comprehensive overview of the development of monthly prices of oncological drugs introduced over the last 15 years in Switzerland. We identified all oncological drugs newly reimbursed by mandatory health insurance in 2005-2019, and searched public repositories for their package prices, indications with approval dates, and treatment regimens for the calculation of (indication-specific) monthly prices. We found 81 products covering 77 different substances (39.5% protein kinase inhibitors, 21.0% monoclonal antibodies). Most indications related to the topography "blood", followed by "lung and thorax" and "digestive tract". From 2005-2009 to 2015-2019, the median monthly product price over all distinct indications of all products decreased by 7.56% (CHF 5,699 [interquartile range 4,483-7,321] to CHF 5,268 [4,19-6,967]), whereas it increased by 73.7% for monoclonal antibodies. In December 2019, six products had monthly prices over CHF 10,000, all approved for hematological or dermatological cancers. Our analysis suggests that individual price developments of oncological drugs are presently not the major driver of rising cancer treatment costs. However, rising launch prices of some new, mostly hematological drugs are of concern and require continued monitoring.
format	article
author	Yael Rachamin Christoph Jakob Ackermann Oliver Senn Thomas Grischott
author_facet	Yael Rachamin Christoph Jakob Ackermann Oliver Senn Thomas Grischott
author_sort	Yael Rachamin
title	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
title_short	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
title_full	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
title_fullStr	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
title_full_unstemmed	Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.
title_sort	price trends of reimbursed oncological drugs in switzerland in 2005-2019: a descriptive analysis.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/7cceb14eaa2541c6b333e1e614f3fbb9
work_keys_str_mv	AT yaelrachamin pricetrendsofreimbursedoncologicaldrugsinswitzerlandin20052019adescriptiveanalysis AT christophjakobackermann pricetrendsofreimbursedoncologicaldrugsinswitzerlandin20052019adescriptiveanalysis AT oliversenn pricetrendsofreimbursedoncologicaldrugsinswitzerlandin20052019adescriptiveanalysis AT thomasgrischott pricetrendsofreimbursedoncologicaldrugsinswitzerlandin20052019adescriptiveanalysis
_version_	1718374833930108928

Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

Ejemplares similares